- Home
- COE vs CTMX Comparison
COE vs CTMX Comparison
Compare COE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- CTMX
- Stock Information
- Founded
- COE 2011
- CTMX 2008
- Country
- COE Singapore
- CTMX United States
- Employees
- COE N/A
- CTMX N/A
- Industry
- COE Other Consumer Services
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- CTMX Health Care
- Exchange
- COE Nasdaq
- CTMX Nasdaq
- Market Cap
- COE 91.5M
- CTMX 89.1M
- IPO Year
- COE 2016
- CTMX 2015
- Fundamental
- Price
- COE $14.20
- CTMX $0.91
- Analyst Decision
- COE
- CTMX Buy
- Analyst Count
- COE 0
- CTMX 6
- Target Price
- COE N/A
- CTMX $5.77
- AVG Volume (30 Days)
- COE 5.1K
- CTMX 1.1M
- Earning Date
- COE 12-16-2024
- CTMX 11-07-2024
- Dividend Yield
- COE N/A
- CTMX N/A
- EPS Growth
- COE N/A
- CTMX N/A
- EPS
- COE N/A
- CTMX 0.16
- Revenue
- COE $35,705,000.00
- CTMX $126,617,000.00
- Revenue This Year
- COE N/A
- CTMX $11.79
- Revenue Next Year
- COE N/A
- CTMX N/A
- P/E Ratio
- COE N/A
- CTMX $5.63
- Revenue Growth
- COE 66.41
- CTMX 33.66
- 52 Week Low
- COE $6.00
- CTMX $0.91
- 52 Week High
- COE $19.75
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- COE 41.35
- CTMX 32.42
- Support Level
- COE $14.01
- CTMX $0.98
- Resistance Level
- COE $15.00
- CTMX $1.08
- Average True Range (ATR)
- COE 0.56
- CTMX 0.06
- MACD
- COE -0.13
- CTMX -0.00
- Stochastic Oscillator
- COE 8.88
- CTMX 0.00
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.